Objectives/Hypothesis: To evaluate antitumor efficacy of the generic mammalian target of rapamycin (mTOR) inhibitor sirolimus in preclinical animal models of head and neck squamous cell carcinoma (HNSCC) and compare its effects with those of the patented analogue temsirolimus.
INTRODUCTION
Rapamycin is a mammalian target of rapamycin (mTOR) inhibitor that was initially isolated more than 30 years ago from Streptomyces hygroscopicus on Easter Island (also known as Rapa Nui) and used as an antifungal agent. 1 It was soon found to have immunosuppressive and antiproliferative effects on human tumor cells by the inhibition of mTOR. 2 The PI3K/Akt/ mTOR kinase pathway is a major regulator of cell proliferation, metabolism, survival, and angiogenesis. 3, 4 In many cancers, including head and neck squamous cell carcinoma (HNSCC), this pathway is upregulated. 5 mTOR phosphorylates and inactivates the translation suppressor initiation factor 4E-binding protein 1 (4E-BP1) and activates ribosomal p 70 S6 kinase (S6K1). 6 The mTOR pathway presents an attractive therapeutic target by acting downstream of broader function upstream proteins in the PI3K/Akt pathway. 7 Owing to the promising effects of mTOR inhibitors, a number of rapamycin analogues have been developed.
Sirolimus was the first rapalogue introduced on the market. It was initially used for its immunosuppressive properties in organ-transplant recipients. 8 Through these patients, sirolimus was also found to inhibit growth of smooth muscle cells; this finding led to its use in drug-eluting stents. 9 In post-transplant patients, sirolimus was seen to cause regression of Kaposi's sarcoma and renal angiomyolipomas in tuberous sclerosis. 10, 11 Phase I studies have been performed using sirolimus in combination with chemotherapy to treat acute myelogenous leukemia and have shown the possibility of combined therapy. 12 The role of sirolimus in combination with other chemotherapeutic agents to treat advanced colorectal cancer is also promising. 13 Currently, prospective randomized controlled studies are underway looking at the effects of sirolimus in preventing nonmelanoma skin cancers and the recurrence of hepatocellular carcinoma in post-transplant patients.
Since the patent for the anticancer application of rapamycin (sirolimus) expired in 1993, other rapalogues have been introduced. Wyeth patented an intravenous form, temsirolimus, in 2007. Novartis recently revealed an oral rapalogue, everolimus. Merck and Ariad Pharmaceuticals most recently codeveloped ridaforolimus.
Early phase clinical trials have demonstrated these rapalogues to be effective in treating refractory mantle cell lymphoma, glioblastoma, breast cancer, endometrial cancer, non-Hodgkin lymphomas, and multiple myeloma. 16 Temsirolimus and everolimus are currently approved by the Food and Drug Administration for treatment of renal cell carcinoma. 17 In HNSCC, we have shown that temsirolimus can inhibit tumor growth and increase tumor-free rates. 18 We have also demonstrated that temsirolimus has radiosensitizing effects in an experimental model of HNSCC. 19 Rapalogues also demonstrate a relatively low side effect profile when used for extended periods in renal transplant patients and angioplasty patients who use rapalogues as immunosuppressant and antiproliferative agents, respectively. 20 With the increasing numbers of designer drugs on the market and an increasing emphasis on biosimilars and generics, there has been a rising focus on determining the cost and comparative effectiveness of drugs. The main goals of this study are to evaluate antitumor efficacy of the cheaper generic mTOR inhibitor sirolimus in an in vivo HNSCC animal model and to compare its effectiveness with patented analogue temsirolimus.
MATERIALS AND METHODS

Cell Line
The eIF4E-overexpressing HNSCC cell line FaDu, derived from a hypopharyngeal squamous cell carcinoma (obtained from American Type Culture Collection, Manassas, VA) was grown in RPMI 1640 (Life Technologies, Grand Island, NY), supplemented with 10% bovine calf serum and nonessential amino acids (Life Technologies). Cells were grown in monolayers and maintained in humidified 5% CO 2 atmosphere at 37 C. All chemicals were obtained from Sigma-Aldrich (St. Louis, MO), except for sirolimus, which was obtained from LC Laboratories (Woburn, MA).
Established Tumor Model
BALB/c nu/nu mice (Charles River Laboratories, Wilmington, MA) were injected with 1 Â 10 6 FaDu cells subcutaneously. Animals were housed in a barrier facility and maintained on a normal diet ad libitum. All studies were conducted in compliance with the Louisiana State University Health Sciences Center Institutional Animal Care and Use Committee guidelines. Tumor volume was determined with digital caliper, (length Â width 2 )/2, and established at a volume of 50 to 60 mm 3 . Animals were randomized into five groups of five mice each and treated with vehicle or sirolimus at a daily intraperitoneal dose of 5, 10, 15, and 20 mg/kg for 5 days per week for 3 weeks. Sirolimus was prepared in 4% ethanol, 5.2% Tween 80, and 5.2% polyethylene glycol 400 (Sigma-Aldrich). Tumor volumes were measured three times per week.
Minimal Residual Disease Model
Nude mice were anesthetized, incisions were made in the dorsal flanks, and subcutaneous flaps were elevated with sharp dissection. Pipette dispensers were used to introduce tumor cells (1 Â 10 6 FaDu cells) in 100 lL saline into the flap, which was then sutured. At 72 hours following tumor seeding, the animals were randomized into two groups: 10 mice in the control group and 21 mice treated with sirolimus 5 mg/kg daily for 5 days per week until the end of the experiment. Tumor volume was determined with digital calipers with the formula (length Â width 2 )/2. Mice were sacrificed due to significant tumor burden (>2,000 mm 3 ), weight loss >15%, or at a maximum time point of 30 days after treatment initiation. As a surrogate marker of toxicity, body weight was measured weekly for the duration of the experiment at the time of tumor measurement without any differences observed between treated and control animals (Supplemental Figure 1 ).
Western Blot Analysis of 4E-BP1 and S6 Ribosomal Protein
Protein was extracted from tumor samples following treatment with sirolimus to confirm the observed effects of sirolimus from mTOR inhibition. Western blot analysis was performed according to previously published laboratory protocol. 21 The following antibodies were used: rabbit polyclonal anti-4E-BP1 (1:500), rabbit anti-S6 ribosomal protein (1:100), and rabbit anti-phospho-S6 ribosomal protein (Ser 235/236 ;1:100); all antibodies were obtained from Cell Signaling (Beverly, MA).
RESULTS
Sirolimus Is as Effective as Temsirolimus in Inhibiting HNSCC Tumor Growth
The effect of sirolimus on tumor growth was evaluated in an established xenograft tumor model (Table I) . Using the established tumor model (ETM), we determined that all doses of sirolimus (5-20 mg/kg) significantly inhibited the growth of FaDu xenograft tumor as compared with control (P < .01; repeated measures analysis of variance [ANOVA] with the Bonferroni post-test). When the results of this study were compared with the results of our published study on the effects of temsirolimus, 18 there were no significant differences in tumor volumes between sirolimus and temsirolimus at 5, 15, and 20 mg/kg (Table I) . Interestingly, at 10 mg/kg, sirolimus performed significantly better than temsirolimus in preventing tumor growth (P < .01; the Wilcoxon rank sum test). Therefore, sirolimus was at least as effective as temsirolimus in inhibiting HNSCC tumor growth.
The Efficacy of Sirolimus in a Minimal Residual Disease Model
The effect of sirolimus was also tested in a minimal residual disease (MRD) model. Tumor formation was measured up to day 30 after sirolimus treatment initiation (5 mg/kg) and compared to control mice (Fig. 1A) . Similarly to its effects in ETM, sirolimus significantly inhibited tumor growth compared to control in the MRD model as well (P < .001). On closer inspection of the tumor growth curve, it appears that on the days of no treatment, the rate of tumor growth increased (Fig. 1B) . This observation may imply that continuous treatment of sirolimus may provide better results in inhibiting tumor growth than a cyclical treatment regimen. Sirolimus demonstrated a significant improvement in survival compared to control on the Kaplan-Meier survival curve, P < .01 (Fig. 2) . Among the control mice, 60% had been sacrificed by the end of the study with median survival time of 27.5 days. All the mice treated with sirolimus survived until the end of the study.
The Effects of Sirolimus on mTOR Signaling
Inhibition of mTOR signaling by sirolimus in tumor tissues was assessed with Western blot analysis. Treatment with sirolimus (5 mg/kg) led to an inhibition in the phosphorylation of 4E-BP1 with a decrease in the phosphorylated c isoform and an increase of the b isoform and unphosphorylated a isoform (Fig. 3) . Sirolimus also decreased pS6 expression by 64.9%, a finding that was comparable to the effects of temsirolimus treatment in our previous study. 20 These analyses confirmed the activity of sirolimus used in our study.
DISCUSSION
HNSCC accounts for 4% of all malignancies in the country. Locoregionally advanced head and neck cancer is treated with multimodality therapy consisting of either definitive concurrent chemoradiotherapy or resection followed by postoperative radiotherapy. 22 However, high-risk HNSCC patients with locally advanced stage III and IV tumors demonstrate a 50% to 60% recurrence rate. The addition of complementary drugs such as targeted agents to the concurrent chemoradiotherapy regimen has shown promise in optimizing treatment by potentially increasing survival rates and decreasing recurrence rates.
Molecular targeting agents have been used successfully in treatment of other cancers. Trastuzumab, a monoclonal antibody that binds and inhibits HER2/neu receptors, is now an integral part of breast cancer treatment for qualifying patients. Imatinib, a tyrosine kinase inhibitor, is used in the treatment of chronic myelogenous leukemia. In HNSCC, cetuximab is a monoclonal antibody that inhibits epidermal growth factor receptors used in combination or alone to treat metastatic disease. Another emerging targeting agent is rapamycin, an mTOR inhibitor.
Rapamycin is an mTOR inhibitor that has an established effect on suppressing tumor growth in a number of solid tumors. It has demonstrated antiproliferative effects and apoptosis in HNSCC cell lines. 4 We previously demonstrated that temsirolimus can inhibit tumor growth in a HNSCC animal model and increase the tumor-free period in MRD. 18 We have also shown that temsirolimus radiosensitizes HNSCC in vivo. 19 A case report further supports potential radiosensitizing properties of the rapalogues in HNSCC. It describes a patient who had undergone liver transplant, developed laryngeal cancer, and was subsequently switched to sirolimus (2 mg daily) from tacrolimus. The patient was then treated with radiation for his HNSCC and demonstrated an exceptional response to therapy with complete resolution of the tumor. 23 As research and clinical evidence continue to confirm the effectiveness of mTOR inhibitors as anticancer agents, the number of commercially available rapamycin analogues has increased. There are a handful of rapamycin-related mTOR inhibitors on the market, at varying costs. Sirolimus, the first introduced rapamycin analogue, currently costs $20 to $37 per day for 4 mg (generic form). Temsirolimus, a rapamycin analogue introduced in 2007 by Wyeth, carries a cost of $1,916 for one 25-mg intravenous treatment which is given once a week. In 2009, Novartis revealed another oral version of rapamycin, pricing their drug everolimus at $99 for 5 mg.
Furthermore, the cost-effectiveness of drug treatment is becoming an increasing focus in today's healthcare spending. Generic drugs have moderated drug expenditures, and health-care reform initiatives are looking into biosimilars legislation. 24 These changes will most likely affect drug treatment plans, including the delivery of combined chemoradiotherapy regimens, in the future.
As research begins to reveal that rapamycin analogues have the potential to serve as complementary agents in treatment of HNSCC, drug comparison and effectiveness studies will help determine the clinical applicability and cost-effectiveness of future drug therapies. The purpose of this study was to evaluate the efficacy of the generic mTOR inhibitor sirolimus in HNSCC and compare its effectiveness to the patented analogue temsirolimus.
We showed that sirolimus significantly inhibits tumor growth at all dosages (5-20 mg/kg) compared to control (P < .01; repeated measures ANOVA with the Bonferroni post-test). In the MRD model, sirolimus slowed the growth of tumors and increased survival, similar to previous studies of temsirolimus. 18 Using weight as a marker of toxicity, we observed no significant difference in weights of treated mice, suggesting the toxicity of sirolimus is low. Finally, in the ETM, when we compared the results of the current study with the results of our published study on the effects of temsirolimus, 18 there was no significant difference in antitumor activity between sirolimus and temsirolimus. This information suggests that sirolimus has the potential to provide equally effective results in the clinical setting as a complementary agent in HNSCC as more expensive patented rapamycin analogues. A better approach would perhaps have been to directly compare sirolimus and temsirolimus in a randomized study of mice. However, our previous study with temsirolimus was performed in a similar fashion, as to provide an adequate historic control for our current study with sirolimus. Future studies may be considered comparing a 5-day treatment regimen with a 7-day regimen of both sirolimus and temsirolimus.
We found that final tumor volumes were relatively similar in the ETM, despite increasing dosages of the drug at 5, 10, 15, and 20 mg/kg. This suggests that higher dosages of sirolimus may not provide any additional benefit in preventing HNSCC tumor growth. Guba et al. found a similar pattern in their studies of rapamycin in tumor growth in mice. They went on to claim that tumor volumes were most effectively controlled with lower dosages of rapamycin. The inhibitory effect of rapamycin on angiogenesis and growth was found to be optimal at lower ranges. They speculate that this finding may be due to increasing side effects and immunosuppression induced by higher concentrations of the drug. This may in turn provide conditions advantageous for cancer growth. 25 Our data also suggest that a treatment regimen of 7 days per week may produce better outcomes than one of 5 days per week. These findings will be applied to a multi-institutional phase I clinical trial looking at treatment of advanced head and neck cancers with everolimus.
This study confirmed that the generic mTOR inhibitor sirolimus demonstrates potent antitumorigenic effects on HNSCC xenografts. Furthermore, there was no significant difference between sirolimus and patented analogue temsirolimus. Additional studies comparing rapamycin analogues should also be constructed to include other analogues such as everolimus and ridaforolimus, which are currently on the market. Our studies also showed that sirolimus inhibited the mTOR pathway, as a decrease in pS6 and a shift in the phosphorylated isoforms of 4EBP1 were observed. Although other markers could have been evaluated, these particular markers have been used in our previous publications for mTOR inhibitors. 26 A decrease in pS6 is also a well-accepted marker for mTOR activity. 27 Ultimately, our findings need to be confirmed in the clinical setting, comparing the effectiveness of rapamycin analogues in treatment of HNSCC patients.
CONCLUSION
This study demonstrated potent antitumor activity of sirolimus in HNSCC and showed that both sirolimus, which is a cheaper generic rapamycin, and temsirolimus, which is a more expensive patented rapamycin analogue, have comparable effectiveness in inhibiting tumor growth in an HNSCC animal model. In the future, sirolimus could serve as a cost-effective complementary agent in the treatment of HNSCC.
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